These findings suggest that Cx32 is a potential therapeutic target and that luteolin represents a promising chemopreventive agent for NASH and NASH-related hepatocarcinogenesis [74]. The gene discussed is GJB1; the disease is metabolic dysfunction-associated steatohepatitis.